Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln - JSPR News | RalliesJasper Therapeutics Q2 loss per share beats estimates, raises $132 mln
J
JSPR• Analyst coverage
- The average analyst rating on the shares is buy.
- The breakdown of recommendations is 4 strong buy or buy, 2 hold and no sell or strong sell ratings.
- Wall Street’s median 12-month price target for Jasper Therapeutics, Inc. is $6.00, about 595.2% above its Aug. 13 closing price of $0.86.
Pipeline and outlook
- Jasper said it completed the acquisition of Kira Pharmaceuticals in July, expanding its clinical portfolio.
- The company expects interim data from the KP-104 Phase 2 basket trial in Q4 2026.
- Jasper expects to announce next steps for KP-104 in PNH in H1 2027.
- The company said current cash is expected to fund operations through H2 2028.
Development priorities
- Jasper plans to advance KP-104, briquilimab and KP-701 in multiple indications, according to the company update.
- CEO Jeet Mahal said the Kira acquisition expanded the company’s clinical pipeline and resources.
Q2 loss beats estimates, company raises $132 million
- Jasper Therapeutics said its fiscal second-quarter net loss per share was $0.10, beating analyst expectations of $0.35.
- The company reported second-quarter net loss of $2.80 million.
- Jasper raised $132 million in gross proceeds through a private investment in public equity (PIPE) financing to support operations through 2028.
